<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Blake Toves</title><link>https://blaketoves.com/</link><description>Articles on payments, business financing and telehealth.</description><item><title>Buy vs. build: the first decision in a 2026 telehealth launch</title><description>What to license and what to own when you launch a telehealth brand.</description><link>https://blaketoves.com/blog/buy-vs-build-telehealth/</link><guid>https://blaketoves.com/blog/buy-vs-build-telehealth/</guid><pubDate>Sun, 11 Oct 2026 00:00:00 GMT</pubDate></item><item><title>Launching a telehealth brand in 2026: notes from my podcast with Mark Lombardi</title><description>Key takeaways from my fireside chat with Mark Lombardi on distribution, margins, buy vs. build, med spas and exits.</description><link>https://blaketoves.com/blog/launching-a-telehealth-brand-2026-mark-lombardi/</link><guid>https://blaketoves.com/blog/launching-a-telehealth-brand-2026-mark-lombardi/</guid><pubDate>Sun, 11 Oct 2026 00:00:00 GMT</pubDate></item><item><title>Why research-only peptide brands should be planning their next move</title><description>Rising enforcement, payment risk and no exit value: the case for building a telehealth brand.</description><link>https://blaketoves.com/blog/research-to-telehealth/</link><guid>https://blaketoves.com/blog/research-to-telehealth/</guid><pubDate>Sun, 11 Oct 2026 00:00:00 GMT</pubDate></item></channel></rss>